Mouse Anti-FKBP14 Recombinant Antibody (3F4) (CBMAB-F1566-CQ)

Name: Mouse Anti-FKBP14 Recombinant Antibody (3F4)
SKU: CBMAB-F1566-CQ
Rating: 5 (1 reviews)

See all FKBP14 antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

3F4

Application

ELISA, WB

Immunogen

Recombinant human FKBP14 (amino acids 20-211).

Specificity

Human

Antibody Isotype

IgG2b, κ

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Buffer

PBS

Preservative

Sodium azide

Concentration

1 mg/ml

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

More Infomation

Target

Full Name

FK506 Binding Protein 14

Introduction

The protein encoded by this gene is a member of the FK506-binding protein family of peptidyl-prolyl cis-trans isomerases. The encoded protein is found in the lumen of the endoplasmic reticulum, where it is thought to accelerate protein folding. Defects in this gene are a cause of a type of Ehlers-Danlos syndrome (EDS). Both a protein-coding variant and noncoding variants are transcribed from this gene.

Entrez Gene ID

55033

UniProt ID

Q9NWM8

Alternative Names

FK506 Binding Protein 14; FK506 Binding Protein 14, 22 KDa; 22 KDa FK506-Binding Protein; PPIase FKBP14; 22 KDa FKBP; Rotamase; FKBP-22; FKBP22; Peptidyl-Prolyl Cis-Trans Isomerase FKBP14;

Function

PPIase which accelerates the folding of proteins during protein synthesis. Has a preference for substrates containing 4-hydroxylproline modifications, including type III collagen. May also target type VI and type X collagens.

Cellular Location

Endoplasmic reticulum lumen

Involvement in disease

Ehlers-Danlos syndrome, kyphoscoliotic type, 2 (EDSKSCL2):
A form of Ehlers-Danlos syndrome, a group of connective tissue disorders characterized by skin hyperextensibility, articular hypermobility, and tissue fragility. EDSKSCL2 is an autosomal recessive form characterized by severe generalized hypotonia at birth, myopathy, early-onset progressive kyphoscoliosis, joint hypermobility without contractures, hyperelastic skin with follicular hyperkeratosis, easy bruising, and occasional abnormal scarring, sensorineural hearing impairment, and normal pyridinoline excretion in urine.

Semyachkina, A. N., Nikolaeva, E. A., Galeeva, N. M., Polyakov, A. V., Kurnikova, M. A., Belova, V. А., ... & Dzhivanshiryan, G. V. (2021). Ehlers-Danlos syndrome kyphoscoliotic type 2 caused by mutations in the FKBP14 gene: An analysis of five cases. F1000Research, 10(502), 502.

Colman, M., Vroman, R., Dhooge, T., Malfait, Z., Symoens, S., Burnyté, B., ... & Syx, D. (2022). Kyphoscoliotic Ehlers‐Danlos syndrome caused by pathogenic variants in FKBP14: Further insights into the phenotypic spectrum and pathogenic mechanisms. Human Mutation, 43(12), 1994-2009.

Bai, Y., Li, L., & Zhang, Z. (2022). Linc00883 affects colorectal cancer through miR-577/FKBP14 axis: a novel mechanism for regulating colorectal cancer cell proliferation, invasion, and migration. Cell Cycle, 21(22), 2403-2416.

Yang, L., Zhang, R., Yang, J., Bi, T., & Zhou, S. (2019). FKBP14 promotes the proliferation and migration of colon carcinoma cells through targeting IL-6/STAT3 signaling pathway. OncoTargets and therapy, 12, 9069.

Giunta, C., Rohrbach, M., Fauth, C., Baumann, M., Adam, M. P., Ardinger, H. H., ... & Amemiva, A. (2019). FKBP14 Kyphoscoliotic Ehlers-Danlos syndrome.

Lim, P. J., Lindert, U., Opitz, L., Hausser, I., Rohrbach, M., & Giunta, C. (2019). Transcriptome profiling of primary skin fibroblasts reveal distinct molecular features between PLOD1-and FKBP14-kyphoscoliotic Ehlers–Danlos syndrome. Genes, 10(7), 517.

Ghoorun, R. A., Wu, X. H., Chen, H. L., Ren, D. L., & Wu, X. B. (2019). Prognostic significance of fkbp14 in gastric cancer. OncoTargets and therapy, 12, 11567.

Castori, M., Fiorillo, C., Agolini, E., Sacco, M., Minetti, C., Novelli, A., ... & Bertini, E. (2019). Primary muscle involvement in a 15‐year‐old girl with the recurrent homozygous c. 362dupC variant in FKBP14. American Journal of Medical Genetics Part A, 179(2), 317-321.

Giunta, C., Baumann, M., Fauth, C., Lindert, U., Abdalla, E. M., Brady, A. F., ... & Rohrbach, M. (2018). A cohort of 17 patients with kyphoscoliotic Ehlers–Danlos syndrome caused by biallelic mutations in FKBP14: expansion of the clinical and mutational spectrum and description of the natural history. Genetics in Medicine, 20(1), 42-54.

Wang, K., Qi, X. J., Liu, H. Z., & Su, H. (2018). MiR-361 inhibits osteosarcoma cell lines invasion and proliferation by targeting FKBP14. Eur Rev Med Pharmacol Sci, 22(1), 79-86.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-FKBP14 Recombinant Antibody (3F4)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Related Products

Mouse Anti-FKBP14 Recombinant Antibody (CBXF-3045) (CAT#: CBMAB-F3747-CQ)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry